ArticleDiscover oncology2025
Primary capicua transcriptional repressor-rearranged sarcoma in the thyroid gland with cervical lymph node and lung metastases: a case report and literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capicua transcriptional repressor (CIC)-rearranged sarcoma (CRS) is a rare and highly aggressive malignant soft tissue small round cell sarcoma. Most CRS tumors occur in the soft tissues of the limbs and trunk and cases in the thyroid gland are extremely rare, with no extant reports in an adult thyroid. This report aims to familiarize clinicians and pathologists with CRS in the thyroid gland, thereby helping them identify new cases, and provide pathological evidence for comprehensive diagnosis and treatment. A 30-year-old woman presented with an asymptomatic right thyroid mass of 5 months. Neck ultrasonography revealed a hypoechoic hypervascular nodule with a maximum diameter of 5 cm. The noncalcified nodule was classified as Ti-RADS 4a. Besides thyroid dysfunction, her thyroglobulin and anti-thyroid peroxidase antibody concentrations were 35.83 IU/mL and > 1,000.00 IU/mL, respectively. CRS was diagnosed based on the histomorphology, immunohistochemistry, and molecular genetics results. The patient opted for further treatment at Zhejiang Cancer Hospital. Ten months after surgical removal, positron emission tomography/computed tomography revealed tumor metastasis to the cervical lymph nodes and lungs. In February 2023, the patient underwent postoperative adjuvant radiotherapy for the tumor bed and cervical lymph nodes and received doses of PGTVtb 6,000 cGy/30F/DT and PTV 5,400 cGy/30F/DT. The patient last visited the clinic in May 2024 due to fever, fatigue, diarrhea, and other symptoms. CRS in solid organs is extremely rare; however, when the morphology shows multinodular, small, round cells with mild-to-moderate atypia, vacuolated nuclei, and prominent nucleoli, it should be considered as a potential differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.